Skip to main content
Top
Published in: Respiratory Research 1/2005

Open Access 01-12-2005 | Research

Health-related quality of life in patients with pulmonary arterial hypertension

Authors: Darren B Taichman, Jennifer Shin, Laryssa Hud, Christine Archer-Chicko, Sandra Kaplan, Jeffery S Sager, Robert Gallop, Jason Christie, John Hansen-Flaschen, Harold Palevsky

Published in: Respiratory Research | Issue 1/2005

Login to get access

Abstract

Background

Improved outcomes with expanding treatment options for patients with pulmonary arterial hypertension present the opportunity to consider additional end-points in approaching therapy, including factors that influence health-related quality of life. However, comparatively little is known about health-related quality of life and its determinants in patients with pulmonary arterial hypertension.

Methods

Health-related quality of life was evaluated in a cross sectional study of 155 outpatients with pulmonary arterial hypertension using generic and respiratory-disease specific measurement tools. Most patients had either World Health Organization functional Class II or III symptoms. Demographic, hemodynamic and treatment variables were assessed for association with health-related quality of life scores.

Results

Patients with pulmonary arterial hypertension suffered severe impairments in both physical and emotional domains of health-related quality of life. Patients with idiopathic ("primary") pulmonary arterial hypertension had the best, and those with systemic sclerosis the worst health-related quality of life. Greater six-minute walk distance correlated with better health-related quality of life scores, as did functional Class II versus Class III symptoms. Hemodynamic measurements, however, did not correlate with health-related quality of life scores. No differences in health-related quality of life were found between patients who were being treated with calcium channel antagonists, bosentan or continuously infused epoprostenol at the time of quality of life assessment.

Conclusion

Health-related quality of life is severely impaired in patients with pulmonary arterial hypertension and is associated with measures of functional status. Specific associations with impaired health-related quality of life suggest potential areas for targeted intervention.
Literature
2.
go back to reference Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK: Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987, 107:216–223.CrossRefPubMed Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK: Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987, 107:216–223.CrossRefPubMed
3.
go back to reference D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, et al.: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343–349.CrossRefPubMed D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, et al.: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343–349.CrossRefPubMed
4.
go back to reference Rubin LJ, Galie N: Pulmonary arterial hypertension: a look to the future. J Am Coll Cardiol 2004, 43:89S-90S.CrossRefPubMed Rubin LJ, Galie N: Pulmonary arterial hypertension: a look to the future. J Am Coll Cardiol 2004, 43:89S-90S.CrossRefPubMed
5.
go back to reference Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, Torbicki A: End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004, 43:48S-55S.CrossRefPubMed Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, Torbicki A: End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004, 43:48S-55S.CrossRefPubMed
6.
go back to reference Highland KB, Strange C, Mazur J, Simpson KN: Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest 2003, 124:2087–2092.CrossRefPubMed Highland KB, Strange C, Mazur J, Simpson KN: Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest 2003, 124:2087–2092.CrossRefPubMed
7.
go back to reference McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, Loyd JE: Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004, 126:14S-34S.CrossRefPubMed McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, Loyd JE: Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004, 126:14S-34S.CrossRefPubMed
8.
go back to reference Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S: Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:40S-47S.CrossRefPubMed Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S: Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:40S-47S.CrossRefPubMed
9.
go back to reference Ware JEKMDJE: How to Score Version 2 of the SF-36 Health Survey. Lincoln, RI, QualityMetric Incorporated; 2000:229. Ware JEKMDJE: How to Score Version 2 of the SF-36 Health Survey. Lincoln, RI, QualityMetric Incorporated; 2000:229.
10.
go back to reference Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145:1321–1327.CrossRefPubMed Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145:1321–1327.CrossRefPubMed
11.
go back to reference Jones PW, Spencer S, Adie S: The St. George's Respiratory Questionnaire Manual, Version 2.1. London, St. George's Hospital Medical School; 2003. Jones PW, Spencer S, Adie S: The St. George's Respiratory Questionnaire Manual, Version 2.1. London, St. George's Hospital Medical School; 2003.
12.
go back to reference Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W: Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322–329.CrossRefPubMed Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W: Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322–329.CrossRefPubMed
13.
go back to reference Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334:296–302.CrossRefPubMed Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334:296–302.CrossRefPubMed
14.
go back to reference Archibald CJ, Auger WR, Fedullo PF, Channick RN, Kerr KM, Jamieson SW, Kapelanski DP, Watt CN, Moser KM: Long-term outcome after pulmonary thromboendarterectomy. Am J Respir Crit Care Med 1999, 160:523–528.CrossRefPubMed Archibald CJ, Auger WR, Fedullo PF, Channick RN, Kerr KM, Jamieson SW, Kapelanski DP, Watt CN, Moser KM: Long-term outcome after pulmonary thromboendarterectomy. Am J Respir Crit Care Med 1999, 160:523–528.CrossRefPubMed
15.
go back to reference Sastry BK, Narasimhan C, Reddy NK, Raju BS: Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004, 43:1149–1153.CrossRefPubMed Sastry BK, Narasimhan C, Reddy NK, Raju BS: Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004, 43:1149–1153.CrossRefPubMed
16.
go back to reference Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:800–804.CrossRefPubMed Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:800–804.CrossRefPubMed
17.
go back to reference Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK: Health-related quality of life in patients with pulmonary arterial hypertension. Chest 2004, 126:1452–1459.CrossRefPubMed Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK: Health-related quality of life in patients with pulmonary arterial hypertension. Chest 2004, 126:1452–1459.CrossRefPubMed
18.
go back to reference Ware JEJ, Gandek B: Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998, 51:903–912.CrossRefPubMed Ware JEJ, Gandek B: Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998, 51:903–912.CrossRefPubMed
19.
go back to reference Ware JEJ, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473–483.CrossRefPubMed Ware JEJ, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473–483.CrossRefPubMed
20.
go back to reference Cohen RA, Moser DJ, Clark MM, Aloia MS, Cargill BR, Stefanik S, Albrecht A, Tilkemeier P, Forman DE: Neurocognitive functioning and improvement in quality of life following participation in cardiac rehabilitation. Am J Cardiol 1999, 83:1374–1378.CrossRefPubMed Cohen RA, Moser DJ, Clark MM, Aloia MS, Cargill BR, Stefanik S, Albrecht A, Tilkemeier P, Forman DE: Neurocognitive functioning and improvement in quality of life following participation in cardiac rehabilitation. Am J Cardiol 1999, 83:1374–1378.CrossRefPubMed
21.
go back to reference Albertsen PC, Aaronson NK, Muller MJ, Keller SD, Ware JEJ: Health-related quality of life among patients with metastatic prostate cancer. Urology 1997, 49:207–16; discussion 216–7.CrossRefPubMed Albertsen PC, Aaronson NK, Muller MJ, Keller SD, Ware JEJ: Health-related quality of life among patients with metastatic prostate cancer. Urology 1997, 49:207–16; discussion 216–7.CrossRefPubMed
22.
go back to reference Hann DM, Jacobsen PB, Martin SC, Kronish LE, Azzarello LM, Fields KK: Quality of life following bone marrow transplantation for breast cancer: a comparative study. Bone Marrow Transplant 1997, 19:257–264.CrossRefPubMed Hann DM, Jacobsen PB, Martin SC, Kronish LE, Azzarello LM, Fields KK: Quality of life following bone marrow transplantation for breast cancer: a comparative study. Bone Marrow Transplant 1997, 19:257–264.CrossRefPubMed
23.
go back to reference Davidson TA, Caldwell ES, Curtis JR, Hudson LD, Steinberg KP: Reduced quality of life in survivors of acute respiratory distress syndrome compared with critically ill control patients. JAMA 1999, 281:354–360.CrossRefPubMed Davidson TA, Caldwell ES, Curtis JR, Hudson LD, Steinberg KP: Reduced quality of life in survivors of acute respiratory distress syndrome compared with critically ill control patients. JAMA 1999, 281:354–360.CrossRefPubMed
24.
go back to reference Chang JA, Curtis JR, Patrick DL, Raghu G: Assessment of health-related quality of life in patients with interstitial lung disease. Chest 1999, 116:1175–1182.CrossRefPubMed Chang JA, Curtis JR, Patrick DL, Raghu G: Assessment of health-related quality of life in patients with interstitial lung disease. Chest 1999, 116:1175–1182.CrossRefPubMed
25.
go back to reference Mahler DA, Mackowiak JI: Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with COPD. Chest 1995, 107:1585–1589.CrossRefPubMed Mahler DA, Mackowiak JI: Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with COPD. Chest 1995, 107:1585–1589.CrossRefPubMed
26.
go back to reference Lucke KT, Coccia H, Goode JS, Lucke JF: Quality of life in spinal cord injured individuals and their caregivers during the initial 6 months following rehabilitation. Qual Life Res 2004, 13:97–110.CrossRefPubMed Lucke KT, Coccia H, Goode JS, Lucke JF: Quality of life in spinal cord injured individuals and their caregivers during the initial 6 months following rehabilitation. Qual Life Res 2004, 13:97–110.CrossRefPubMed
27.
go back to reference Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE: Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003, 123:344–350.CrossRefPubMed Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE: Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003, 123:344–350.CrossRefPubMed
28.
go back to reference Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM: Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003, 167:580–586.CrossRefPubMed Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM: Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003, 167:580–586.CrossRefPubMed
29.
go back to reference Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TAJ: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000, 132:425–434.CrossRefPubMed Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TAJ: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000, 132:425–434.CrossRefPubMed
30.
go back to reference Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896–903.CrossRefPubMed Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896–903.CrossRefPubMed
31.
go back to reference Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K: Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000, 161:487–492.CrossRefPubMed Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K: Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000, 161:487–492.CrossRefPubMed
32.
go back to reference Doughty NMKSPMDCFPZJ: The CAMPHOR: Correlations with Objective Measures of Severity of Pulmonary Hypertension. Proceedings of the American Thoracic Society 2005, 2:A801. Doughty NMKSPMDCFPZJ: The CAMPHOR: Correlations with Objective Measures of Severity of Pulmonary Hypertension. Proceedings of the American Thoracic Society 2005, 2:A801.
Metadata
Title
Health-related quality of life in patients with pulmonary arterial hypertension
Authors
Darren B Taichman
Jennifer Shin
Laryssa Hud
Christine Archer-Chicko
Sandra Kaplan
Jeffery S Sager
Robert Gallop
Jason Christie
John Hansen-Flaschen
Harold Palevsky
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2005
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-6-92

Other articles of this Issue 1/2005

Respiratory Research 1/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.